Status:
COMPLETED
Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Cardiomyopathy, Hypertrophic
Eligibility:
All Genders
Brief Summary
DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most patients with hypertrophic cardiomyopathy (HCM). Notably, when pacing is temporarily discontinued, the beneficial ...
Detailed Description
DDD pacing improves symptoms and relieves LV outflow tract (LVOT) obstruction in most patients with hypertrophic cardiomyopathy (HCM). Notably, when pacing is temporarily discontinued, the beneficial ...
Eligibility Criteria
Group 1:
HCM patients, aged grater than 20 years of either gender who received DDD pacemakers at the NIH at least 4 years ago, for relief of LVOT obstruction and drug-refractory symptoms.
Group 2:
HCM patients selected from Group 1 who at the follow-up cardiac catheterization are demonstrated to have either (1) no significant LVOT obstruction (less than 30mm HG at rest and less than 50mm HG with Isuprel); or (2) a substantial reduction of the LVOT obstruction (greater than 50% reduction in LVOT gradient).
Patient who have developed a heart block will be excluded from group 2.
Females must have a negative pregnancy test.
Key Trial Info
Start Date :
April 1 1996
Trial Type :
OBSERVATIONAL
End Date :
May 1 2000
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00001530
Start Date
April 1 1996
End Date
May 1 2000
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892